Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP9 | P55211 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668951 | 0.81 | MAOA (0.32) | MAOACES1BCHEALDH1A1CYP1A2 | |
| SCHEMBL995757 | 0.80 | MAOA (0.33) | MAOACES1BCHE | |
| SCHEMBL9154619 | 0.71 | MAOA (0.40) | MAOAACHECES1BCHECYP19A1 | |
| SCHEMBL11802317 | 0.71 | CYP19A1 (0.51) | ACHECES1CYP19A1ALDH1A1TSHR | |
| SCHEMBL183267 | 0.70 | TTK (0.41) | MAOACES1BCHECYP19A1TDP2 | |
| SCHEMBL11775155 | 0.67 | — | — | |
| SCHEMBL9786538 | 0.67 | CYP19A1 (0.43) | CYP19A1TSHRPKMMAOB | |
| SCHEMBL3294807 | 0.66 | ADRA1A (0.36) | CYP19A1CYP1A2 | |
| SCHEMBL7650679 | 0.65 | ACHE (0.46) | MAOAACHECYP19A1METAP1MAOB | |
| SCHEMBL18403517 | 0.62 | MAOB (0.38) | MAOACYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016952-B1 | SPIRO-CONDENSED LACTAM COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | claimed |
| US-20160372681-A1 | SPIRO-CONDENSED LACTAM COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-12-22 | — | — | US | claimed |
| US-6127426-A | ANTIALLERGIC AND -INFLAMMATORY AGENTS E.G., TREATING PSORIASIS, BLOCKED ON THE C-10 BY A NONPHENOLIC ARYLACYL OR A PHENYLALKYLIDENE GROUP; LIPOXYGENASE INHIBITORS; ANTIPROLIFERATIVE AGENTS; LOW DOSAGE; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2000-10-03 | — | — | US | claimed |
| EP-0664780-B1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMA (IL) | 1999-12-08 | — | — | EP | claimed |
| US-5844004-A | 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceuticals | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-12-01 | — | — | US | claimed |
| EP-0664780-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-02 | — | — | EP | claimed |
| WO-1995003266-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-02-02 | — | — | WO | claimed |
| CN-109096239-B | Preparation route of 9-anthrone lactone framework compound and application of analogue thereof in antitumor aspect | 中国海洋大学 | 2022-02-11 | — | — | CN | disclosed |
| US-11121327-B2 | Spiro-condensed lactam compounds for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2021-09-14 | — | — | US | disclosed |
| US-20160372681-A1 | SPIRO-CONDENSED LACTAM COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| WO-2011045404-A2 | COMPOSITION COMPRISING AT LEAST ONE ANTHRONE DERIVATIVE AND ONE BASIFYING AGENT, AND METHOD FOR DYEING KERATINOUS FIBRES STARTING FROM THE COMPOSITION | L'OREAL (FR) | 2011-04-21 | — | — | WO | disclosed |
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | WANG BING | 2010-08-12 | — | — | US | disclosed |
| US-7737179-B2 | Methods for treatment of dermatological conditions | J&J CONSUMER COMPANIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-5844004-A | 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceuticals | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-12-01 | — | — | US | disclosed |
| US-5661187-A | ADMINISTERING TO TREAT AN ALLERGIC OR INFLAMMATORY CONDITION; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-08-26 | — | — | US | disclosed |
| EP-0664780-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-02 | — | — | EP | disclosed |
| US-5426197-A | Antiinflammatory, antiallergy or antitumor agents | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-06-20 | — | — | US | disclosed |
| WO-1995003266-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1995-02-02 | — | — | WO | disclosed |
| US-5340931-A | Chemical intermediates for allyl or vinyl ether polymers | NIPPON PAINT CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0333445-A2 | Aromatic allene compounds and preparation thereof | NIPPON PAINT CO., LTD. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202989-A1 | METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | KRT18, CUTA, TUBB1 | MAOA 299/4885ACHE 692/4885CES1 1193/4885 |
| US-11121327-B2 | Spiro-condensed lactam compounds for organic electroluminescent devices | PORCN, COASY, AAAS | MAOA 2092/4885ACHE 532/4885CES1 4305/4885 |
| US-20160372681-A1 | SPIRO-CONDENSED LACTAM COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | PORCN, COASY, AAAS | MAOA 2092/4885ACHE 532/4885CES1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.